Skip to main content

Table 4 Incremental cost per QALY gained

From: Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany

Treatments ordered from least to most effective Patient-level Population-level (100 MDR patients) Incremental cost per QALY gained (€)
Total cost, € Total QALYs gained Total LYG Total cost, € Total QALYs gained Total LYG Versus BR alone Versus Linezolid plus BR Versus delamanid plus BR
BR alone 60,962 3.68 4.82 6,096,152 368 482 87,484 38,703
Linezolid plus BR 80,460 3.91 5.07 8,045,981 391 507 87,484 2026
Delamanid plus BR 81,079 4.21 5.36 8,107,888 421 536 38,703 2026
Bedaquiline plus BR 85,575 4.79 5.95 8,557,529 479 595 22,238 5787 7774
  1. BR Background Regimen, QALY Quality-Adjusted Life Year, LYG life-years gained